William Keane, Vice President of Strategic Initiatives, Tevogen Bio
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
16 mai 2024 14h00 HE | Tevogen Bio Inc
Former police chief & FBI National Academy graduate, William Keane, to work with functional leads, ensure policies, procure Tevogen’s lab space.
PaxMedica logo.jpg
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
15 mai 2024 08h30 HE | PaxMedica, Inc.
TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the “Company” or “PaxMedica”) (OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for...
Tevogen Logo Notified.png
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
10 mai 2024 17h40 HE | Tevogen Bio Inc
$50 million in financing advances operational objectives and bolsters a financial path to positive cashflow with minimal dilution.
Gene Therapies in De
Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market
01 mai 2024 14h17 HE | Spherix Global Insights
EXTON, PA, May 01, 2024 (GLOBE NEWSWIRE) -- In the landscape of healthcare innovation, retinal disorders, including both inherited and degenerative diseases, have become a leading focus area for...
Tevogen Logo Notified.png
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
01 mai 2024 08h05 HE | Tevogen Bio Inc
For full year 2023, the operating expenses for Tevogen Bio Inc were $8.8 million.
YPrime CNS Survey - Key eCOA Attributes
New YPrime Report Highlights eCOA's Impact on CNS Trials
01 mai 2024 08h00 HE | Y-Prime, LLC
YPrime has released a new report, Insights into CNS Clinical Trials, which demonstrates to sponsors how eCOA can help streamline CNS research.
Figure 1*
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
25 avr. 2024 10h00 HE | Tiziana Life Sciences Ltd.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair
24 avr. 2024 03h00 HE | Harness Therapeutics
Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein...
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
19 avr. 2024 07h00 HE | Tiziana Life Sciences Ltd.
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -- Data presented in a...
Axsome Logo.png
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
15 avr. 2024 07h00 HE | Axsome Therapeutics, Inc.
AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting...